Results 1 to 10 of about 15,946 (118)

The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study [PDF]

BMC Cardiovascular Disorders
Objective To evaluate the effect of dapagliflozin on cardiorespiratory fitness (CRF) in patients with coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM) following percutaneous coronary intervention (PCI).
Jiali Yang, Xinru Li, Liangqiu Tang, Wenmao Fan, Aihua Li, Wanming Zhou, Jungang Pang, Qiuxiao Yuan, Ming Zhong, Jinhui Hou, Lan Wang, Wenjiao Liao, Xiangyang Liu   +12 more
doaj   +2 more sources

Reduction in Albuminuria with Dapagliflozin Exhibits Substantial Interindividual Variability: A Real-World Study Utilizing a Big Data Approach [PDF]

Balkan Medical Journal
Background: Differences in the albuminuria-lowering effect of dapagliflozin and the associated factors require further exploration. Aims: To evaluate interindividual variability in the albuminuria-lowering effect of dapagliflozin and identify factors ...
Jinfang Song, Yongru Zhuang, Chenling Wu, Yi Xu, Ya Chen, Tao Wang, Xiaoxing Yin, Fen Xie   +7 more
doaj   +2 more sources

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity

Anatolian Journal of Cardiology, 2023
Background: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use.
Sebahat Ulusan, Kanat Gülle, Ahmet Peynirci, Murat Sevimli, Adnan Karaibrahimoglu, Mevlüt Serdar Kuyumcu   +5 more
doaj   +1 more source

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients

Frontiers in Pharmacology, 2023
Dapagliflozin has been used to treat patients with type 1 diabetes mellitus; however, the actual drug efficacy of dapagliflozin on glycated hemoglobin (HbA1c) and whether there is a rebound from dapagliflozin efficacy on HbA1c remain unknown. The present
Dong-Dong Wang, Cun Zhang, Ke Hu, Su-Mei He, Ping Zhu, Xiao Chen   +5 more
doaj   +1 more source

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome

Scientific Reports, 2021
The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome.
Lan Cheng, Qianyu Fu, Longhua Zhou, Yuqin Fan, Fenfen Liu, Yuanyuan Fan, Xin Zhang, Weiqing Lin, Xiaohe Wu   +8 more
doaj   +1 more source

The Association between Dapagliflozin Use and the Risk of Post-Contrast Acute Kidney Injury in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity-Matched Analysis

Kidney & Blood Pressure Research, 2023
Introduction: This study aimed to investigate the effect of dapagliflozin in preventing post-contrast acute kidney injury (PC-AKI) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) who underwent an elective coronary procedure ...
Tao Liu, Xinwen Jian, Li Li, Shan Chu, Zeyuan Fan   +4 more
doaj   +1 more source

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes

Frontiers in Endocrinology, 2022
BackgroundMost patients with type 1 diabetes (T1DM) do not reach the blood glucose goal with treatment of insulin. In our research, we intended to estimate the therapeutic effect and safety of additional different doses of dapagliflozin on insulin ...
Yinhui Li, Hui Li, Liming Dong, Dandan Lin, Lijuan Xu, Pengwei Lou, Deng Zang, Kai Wang, Li Ma   +8 more
doaj   +1 more source

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Frontiers in Cardiovascular Medicine, 2022
Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin improves cardiovascular outcomes in patients with type 2 diabetes in a manner that is partially independent of its hypoglycemic effect.
Yong-Wei Yu, Yong-Wei Yu, Jia-Qun Que, Shuai Liu, Kai-Yu Huang, Lu Qian, Ying-Bei Weng, Fang-Ning Rong, Lei Wang, Ying-Ying Zhou, Yang-Jing Xue, Kang-Ting Ji   +11 more
doaj   +1 more source

Dapagliflozin Mitigated Elevated Disomic and Diploid Sperm in a Mouse Model of Diabetes and Recover the Disrupted Ogg1, Parp1, and P53 Gene Expression

Biomedicines, 2023
Increases in numerical chromosomal syndromes were observed in children of diabetic mothers. However, the effects of diabetes on male reproduction, specifically numerical chromosomal aberrations (aneuploidy), have not been studied.
Norah A. Albekairi, Mohammed A. Al-Hamamah, Ali A. Alshamrani, Mohamed S. M. Attia, Ahmed Nadeem, Mushtaq A. Ansari, Sheikh F. Ahmad, Saleh A. Bakheet, Sabry M. Attia   +8 more
doaj   +1 more source

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

Molecules, 2020
Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the ...
Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Hideaki Yokoo, Aya Osaki, Yoko Shimoda, Atsushi Ozawa, Yasuyo Nakajima, Jeffrey E. Pessin, Shuichi Okada, Masanobu Yamada   +10 more
doaj   +1 more source